Drug intelligence / Profile preview

LAU-ATB-04

Development stage: Unknown
Lead developer: Vectans Pharma
Modality: Small Molecules
Administration: Buccal

Overview

LAU-ATB-04 is an investigational antibacterial drug candidate being developed by Vectans Pharma for the treatment of oral infections. It utilizes the proprietary Lauriad mucoadhesive buccal tablet technology, which allows the tablet to adhere to the oral mucosa and release the active antibiotic ingredient in a sustained manner directly at the site of infection. This localized delivery system is intended to provide high therapeutic concentrations in the oral cavity while reducing systemic exposure and associated side effects. LAU-ATB-04 is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on LAU-ATB-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAU-ATB-04.

Explore the full profile